Role of liposomes in chemoimmunotherapy of Breast cancer DOI

Fatemeh Attarian,

Ghazaleh Hatamian,

Shamim Nosrati

et al.

Journal of drug targeting, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 43

Published: Feb. 19, 2025

In the dynamic arena of cancer therapeutics, chemoimmunotherapy has shown tremendous promise, especially for aggressive forms breast like triple-negative (TNBC). This review delves into significant role liposomes in enhancing effectiveness by leveraging cancer-specific mechanisms such as induction immunogenic cell death (ICD), reprogramming tumor microenvironment (TME), and enabling sequential drug release. We examine innovative dual-targeting that capitalize on heterogeneity, well pH-sensitive formulations offer improved control over delivery. Unlike prior analyses, this directly links advancements preclinical research-such PAMAM dendrimer-based nanoplatforms RGD-decorated liposomes-to clinical trial results, highlighting their potential to revolutionize TNBC treatment strategies. Additionally, we address ongoing challenges related scalability, toxicity, regulatory compliance, propose future directions personalized, immune-focused nanomedicine. work not only synthesizes latest research but also offers a framework translating liposomal from laboratory practice.

Language: Английский

Role of liposomes in chemoimmunotherapy of Breast cancer DOI

Fatemeh Attarian,

Ghazaleh Hatamian,

Shamim Nosrati

et al.

Journal of drug targeting, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 43

Published: Feb. 19, 2025

In the dynamic arena of cancer therapeutics, chemoimmunotherapy has shown tremendous promise, especially for aggressive forms breast like triple-negative (TNBC). This review delves into significant role liposomes in enhancing effectiveness by leveraging cancer-specific mechanisms such as induction immunogenic cell death (ICD), reprogramming tumor microenvironment (TME), and enabling sequential drug release. We examine innovative dual-targeting that capitalize on heterogeneity, well pH-sensitive formulations offer improved control over delivery. Unlike prior analyses, this directly links advancements preclinical research-such PAMAM dendrimer-based nanoplatforms RGD-decorated liposomes-to clinical trial results, highlighting their potential to revolutionize TNBC treatment strategies. Additionally, we address ongoing challenges related scalability, toxicity, regulatory compliance, propose future directions personalized, immune-focused nanomedicine. work not only synthesizes latest research but also offers a framework translating liposomal from laboratory practice.

Language: Английский

Citations

0